Prevalence of Tuberculous Spondylodisciitis and Diagnostic Utility of Xpert MTB RIF
Results. 36 patient had culture confirmed pyogenic spondylodisciitis; 17 cases were treated empirically though the tissue culture were negative as HPE was suggestive of pyogenic spondylodisciitis. 3 had non-infective etiology.
Among 30 who were treated as tuberculous spondylosdisciitis, in initial 16 patients genexpert was not done due to non-availability. Among these 16 patients, 1 had confirmed TB as the tissue grew MTB (MDR TB), 15 were treated as probable TB. All patients except one had good outcome. In the 14 patients treated as tuberculous spondylodisciitis in whom genexpert was done, 12 patients had positive genexpert as compared with 7 AFB culture positive patients. In two samples in which genexpert was negative, TB was confirmed by AFB culture and in another by HPE. All patients except one (who had underling lymphoma) improved with ATT. In all other 10 cases where genexpert was negative, the etiology was pyogenic.
Conclusion. Pyogenic spondylodisciitis is more prevalent than tuberculous spondylodisciits in this study. Genexpert in tissue from infective spondylodisciitis is more sensitive than AFB smear and culture in diagnosing tuberculous spondylodisciitis. Background. Drug resistance tuberculosis, specially MDR and XDR are a big challenge for diagnosis and treatment. In Mexico the prevalence of MDR is between 3-5%, a number probably underestimated due to lack of diagnostic tests for susceptibility. The National Institute of Respiratory Diseases in Mexico City is the national referral center for MDR/XDR tuberculosis. In our country there is no data about the gene mutations involved in drug resistance to first line antituberculosis treatment nor the clinical characteristics that accompany these findings.
Objective: Evaluate the prevalence of genotyping profiles according to a line probe assay (LPA) in patients with drug resistance tuberculosis and their associated clinical characteristics Methods. Retrospective cohort from 2010 to 2014 of M. tuberculosis isolates with any type of resistance to first line antituberculosis drugs identified by MGIT SIRE and in which GenoType MTBDRplus/sl were performed, we evaluate prevalence of genotyping profiles according to the LPA within the isolates and gather data from those with complete medical records to asses clinical characteristics.
Results. In 52 and 33 isolates phenotyping and genotyping MTBDRplus/sl respectively were performed, 41 resistant to Isoniazid INH with 75% genotypic concordance, 33 resistant to rifampicin RIF with 75.6% concordance, 14 to streptomycin SM with 23% concordance and 10 to ethambutol EMB with 100% concordance, 54% MDR tuberculosis. 
